Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | RO7283420 |
Trade Name | |
Synonyms | RO-7283420|RO 7283420|RG6007|RG-6007|RG 6007|HLA-A2-WT1 x CD3 RG6007 |
Drug Descriptions |
RO7283420 is a T-cell receptor-like T-cell engaging bispecific antibody (T-BsAb) that targets a 9-amino acid peptide derived from Wilms tumor 1 (WT1) and CD3 expressed on T-lymphocytes, which potentially leads to a cytotoxic T-lymphocyte response against tumor cells expressing WT1 (NCI Drug Dictionary). |
DrugClasses | CD3 Antibody 99 |
CAS Registry Number | NA |
NCIT ID | C188287 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Dasatinib + RO7283420 + Tocilizumab | Dasatinib RO7283420 Tocilizumab | 0 | 1 |
RO7283420 | RO7283420 | 0 | 0 |